ZEISS Vision Care US Names Healthcare Industry Veteran Gary Rosenblum as President and Chief Executive Officer

Most Recently Serving as President for Oticon, a Division of Demant, Rosenblum Brings 30+ Years of Experience in Medical Technology and Consumer Healthcare to ZEISS

HEBRON, Ky.–(BUSINESS WIRE)–ZEISS Vision Care, one of the world’s leading manufacturers of eyeglass lenses and ophthalmic instruments, announced today that Gary Rosenblum has been named President and Chief Executive Officer of ZEISS Vision Care US, effective June 16, 2025. Rosenblum brings relevant senior leadership experience at Demant, Johnson & Johnson, Abbott and Pfizer to his new role. He succeeds Jens Boy, who has spent more than a decade driving the ZEISS Vision Care business in North America, and will depart the company in pursuit of new opportunities on June 30, 2025.

Rosenblum joins ZEISS following more than eight years at Oticon, a division of Demant, where he served as President for US Hearing Aids and led efforts to bring the company’s life-changing hearing solutions to Americans with mild-to-severe hearing loss. Under his leadership, Oticon achieved outstanding results in terms of growing market share and increasing revenue, driven by new approaches in sales, talent development and transformation. Before that, Rosenblum led the Enterprise Customer Team at Johnson & Johnson, working with the largest hospital systems on the West Coast. He’s also served as Director, Global Strategic Marketing at Abbott, leading the charge in the worldwide commercialization of the company’s Diabetes Care portfolio.

“Gary’s hands-on experience in highly relevant healthcare roles and his proven track record of success make him an excellent fit to join the ZEISS Vision Care team,” said Sven Hermann, CEO ZEISS Consumer Markets. “With Gary at the helm, I am confident we will continue our positive momentum and maintain ZEISS’ leadership in the US market. I am incredibly grateful for the role Jens played in transforming ZEISS Vision Care in North America over the past ten years and wish him the best in his future endeavors.”

In his role as president and CEO, Rosenblum will focus on growing ZEISS Vision Care US, both in terms of the core business and future opportunities. Driven by a commitment to protect and improve eye health, he is passionate about continuing the legacy of innovation that has guided ZEISS for more than 179 years.

“I am thrilled to join ZEISS Vision Care and continue to build on the company’s mission of delivering industry-leading optical innovations to eyecare professionals and millions of Americans,” said Rosenblum. “I am already impressed with our incredible team in the US and their commitment to excellence. I’d like to thank Jens for his support with this transition and look forward to continuing his record of success for the company.”

About ZEISS

ZEISS is an internationally leading technology enterprise operating in the fields of optics and optoelectronics. In the previous fiscal year, the ZEISS Group generated annual revenue totaling 10 billion euros in its four segments Semiconductor Manufacturing Technology, Industrial Quality & Research, Medical Technology and Consumer Markets (status: 30 September 2023).

For its customers, ZEISS develops, produces and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for the life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world’s leading lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses and binoculars.

With a portfolio aligned with future growth areas like digitalization, healthcare and Smart Production and a strong brand, ZEISS is shaping the future of technology and constantly advancing the world of optics and related fields with its solutions. The company’s significant, sustainable investments in research and development lay the foundation for the success and continued expansion of ZEISS’ technology and market leadership. ZEISS invests 15 percent of its revenue in research and development – this high level of expenditure has a long tradition at ZEISS and is also an investment in the future.

With over 43,000 employees, ZEISS is active globally in almost 50 countries with around 30 production sites, 60 sales and service companies and 27 research and development facilities (status: 30 September 2023). Founded in 1846 in Jena, the company is headquartered in Oberkochen, Germany. The Carl Zeiss Foundation, one of the largest foundations in Germany committed to the promotion of science, is the sole owner of the holding company, Carl Zeiss AG.

Further information at www.zeiss.com

ZEISS Vision Care

ZEISS Vision Care is one of the world’s leading manufacturers of eyeglass lenses and ophthalmic instruments. The unit is allocated to the Consumer Markets segment and develops and produces offerings for the entire eyeglass value chain that are distributed globally under the ZEISS brand.

Contacts

Press contact
Allison for ZEISS Vision Care

Rebecca Buddingh

Phone: +1 619 207 8007

E-Mail: rebecca.buddingh@allisonworldwide.com

www.zeiss.com/newsroom
www.zeiss.com/vision-news